Assignee
H LUNDBECK AS
DK·208 granted patents·77 pending applications·671 citations·filing 2003–2025
Top patents by PatentIndex Score
285 records- 0198US11707476B2Catecholamine prodrugs for use in the treatment of parkinson's diseaseH LUNDBECK AS·Filed 2021·Granted Jul 25, 2023·12 cites·17 claims
- 0298US11542323B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2020·Granted Jan 3, 2023·6 cites·24 claims
- 0398US11524995B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2020·Granted Dec 13, 2022·6 cites·20 claims
- 0498US11110110B2Catecholamine prodrugs for use in the treatment of Parkinson's diseaseH LUNDBECK AS·Filed 2020·Granted Sep 7, 2021·15 cites·20 claims
- 0598US11104697B2Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acidH LUNDBECK AS·Filed 2020·Granted Aug 31, 2021·14 cites·12 claims
- 0697US12226428B2Catecholamine prodrugs for use in the treatment of Parkinson's diseaseH LUNDBECK AS·Filed 2023·Granted Feb 18, 2025·6 cites·22 claims
- 0797US11938185B2Treatment of headache, migraine and/or photophobia conditions using humanized anti-PACAP antibodiesH LUNDBECK AS·Filed 2020·Granted Mar 26, 2024·3 cites·42 claims
- 0897US11827665B2Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acidH LUNDBECK AS·Filed 2021·Granted Nov 28, 2023·8 cites·21 claims
- 0997US11421024B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2020·Granted Aug 23, 2022·6 cites·23 claims
- 1097US11026923B21H-pyrazolo[4,3-b]pyridines as PDE1 inhibitorsH LUNDBECK AS·Filed 2020·Granted Jun 8, 2021·4 cites·17 claims
- 1197US11026924B21H-pyrazolo[4,3-b]pyridines as PDE1 inhibitorsH LUNDBECK AS·Filed 2020·Granted Jun 8, 2021·4 cites·19 claims
- 1297US10800836B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2016·Granted Oct 13, 2020·10 cites·10 claims
- 1397US10729710B2Catecholamine prodrugs for use in the treatment of Parkinson's diseaseH LUNDBECK AS·Filed 2018·Granted Aug 4, 2020·21 cites·15 claims
- 1497US10647764B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2019·Granted May 12, 2020·9 cites·14 claims
- 1597US10647763B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2019·Granted May 12, 2020·9 cites·14 claims
- 1697US10640554B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2019·Granted May 5, 2020·9 cites·14 claims
- 1796US11866410B2Process for the manufacturing of (6AR,10AR)-7-propyl-6,6A,7,8,9,10,10A,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4AR, 10AR)-1-propyl-1,2,3,4,4A,5,10,10A-octahydro-benzo[G]quinoline-6,7-diolH LUNDBECK AS·Filed 2021·Granted Jan 9, 2024·8 cites·18 claims
- 1896US11858954B2Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acidH LUNDBECK AS·Filed 2021·Granted Jan 2, 2024·8 cites·31 claims
- 1996US11851456B2Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acidH LUNDBECK AS·Filed 2021·Granted Dec 26, 2023·9 cites·23 claims
- 2096US11639380B2Acute treatment and rapid treatment of headache using anti-CGRP antibodiesH LUNDBECK AS·Filed 2020·Granted May 2, 2023·11 cites·11 claims
- 2196US11168056B2Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diolH LUNDBECK AS·Filed 2020·Granted Nov 9, 2021·14 cites·13 claims
- 2296US11130775B2Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acidH LUNDBECK AS·Filed 2020·Granted Sep 28, 2021·14 cites·16 claims
- 2396US11111263B2Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acidH LUNDBECK AS·Filed 2020·Granted Sep 7, 2021·15 cites·18 claims
- 2496US10364285B2Antibodies for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jul 30, 2019·13 cites·9 claims
- 2596US10358484B2Antibodies for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jul 23, 2019·13 cites·9 claims
- 2696US10358483B2Antibodies for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jul 23, 2019·13 cites·9 claims
- 2796US10351561B2Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as PDE1 inhibitorsH LUNDBECK AS·Filed 2017·Granted Jul 16, 2019·12 cites·21 claims
- 2895US12162936B2Methods of treatment with anti-PACAP antibodiesH LUNDBECK AS·Filed 2021·Granted Dec 10, 2024·2 cites·23 claims
- 2995US11993648B2Screening method for identifying anti-PACAP antibodies or antibody fragments suitable for use in treating or preventing PACAP-associated photophobia or light aversionH LUNDBECK AS·Filed 2020·Granted May 28, 2024·3 cites·9 claims
- 3095US11111290B2Antibodies specific for hyperphosphorylated tau and methods of use thereofH LUNDBECK AS·Filed 2019·Granted Sep 7, 2021·6 cites·9 claims
- 3195US10975135B2Humanized anti-PACAP antibodiesH LUNDBECK AS·Filed 2020·Granted Apr 13, 2021·4 cites·34 claims
- 3295US10968268B2Humanized anti-PACAP antibodiesH LUNDBECK AS·Filed 2020·Granted Apr 6, 2021·4 cites·34 claims
- 3395US10954285B2Humanized anti-PACAP antibodiesH LUNDBECK AS·Filed 2020·Granted Mar 23, 2021·4 cites·34 claims
- 3495US10806718B21H-pyrazolo[4,3-b]pyridines as PDE1 inhibitorsH LUNDBECK AS·Filed 2019·Granted Oct 20, 2020·7 cites·16 claims
- 3595US10358482B2Antibodies for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jul 23, 2019·11 cites·9 claims
- 3695US10196439B2Antibodies specific for hyperphosphorylated tau and methods of use thereofH LUNDBECK AS·Filed 2016·Granted Feb 5, 2019·23 cites·20 claims
- 3794US12077578B2Compositions and methods for treating synucleinopathiesH LUNDBECK AS·Filed 2023·Granted Sep 3, 2024·5 cites·16 claims
- 3894US10934348B2Antibodies specific for hyperphosphorylated tau and methods of use thereofH LUNDBECK AS·Filed 2019·Granted Mar 2, 2021·6 cites·11 claims
- 3994US10034861B21H-pyrazolo[4,3-b]pyridines as PDE1 inhibitorsH LUNDBECK AS·Filed 2017·Granted Jul 31, 2018·13 cites·28 claims
- 4093US11548849B2Alcohol derivatives as KV7 potassium channel openersH LUNDBECK AS·Filed 2020·Granted Jan 10, 2023·3 cites·9 claims
- 4193US11491140B21H-pyrazolo[4,3-b]pyridines as PDE1 inhibitorsH LUNDBECK AS·Filed 2020·Granted Nov 8, 2022·2 cites·20 claims
- 4293US11434199B2Alcohol derivatives as KV7 potassium channel openersH LUNDBECK AS·Filed 2020·Granted Sep 6, 2022·4 cites·12 claims
- 4393US11434222B2MAGL inhibitorsH LUNDBECK AS·Filed 2021·Granted Sep 6, 2022·2 cites·12 claims
- 4493US10689379B2Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitorsH LUNDBECK AS·Filed 2019·Granted Jun 23, 2020·6 cites·14 claims
- 4593US10618913B2Macrocycles as PDE1 inhibitorsH LUNDBECK AS·Filed 2018·Granted Apr 14, 2020·7 cites·19 claims
- 4693US10512632B21 H-pyrazolo[4,3-B]pyridines as PDE1 inhibitorsH LUNDBECK AS·Filed 2018·Granted Dec 24, 2019·9 cites·13 claims
- 4792US10889635B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jan 12, 2021·6 cites·20 claims
- 4892US10647762B2Antibodies specific for hyperphosphorylated tau and methods of use thereofH LUNDBECK AS·Filed 2019·Granted May 12, 2020·5 cites·3 claims
- 4992US10479835B2Agent, uses and methods for treatmentH LUNDBECK AS·Filed 2016·Granted Nov 19, 2019·4 cites·16 claims
- 5092US10428147B2Anti-sortilin antibodies, uses and methods for treatmentH LUNDBECK AS·Filed 2016·Granted Oct 1, 2019·4 cites·7 claims
Showing the top 50 of 285 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →